8-K: Exicure Secures $2 Million in Private Stock Placement with SangSangIn Investment

Exicure, Inc. has entered into a definitive agreement to sell 433,332 shares of its common stock to SangSangIn Investment & Securities Co., Ltd. for approximately $2 million.

Summary

• Exicure, Inc. has agreed to sell 433,332 shares of its common stock to SangSangIn Investment & Securities Co., Ltd. at a price of $4.61 per share.
• The transaction is expected to close within ten days of the agreement date, which was December 9, 2024.
• Exicure anticipates receiving gross proceeds of approximately $2 million from this stock sale.
• In connection with the stock purchase, Exicure has also entered into a Registration Rights Agreement with SangSang, agreeing to register the resale of these shares.
• The company is required to file a registration statement for the resale of the shares within 60 days of the closing date and to use its best efforts to have it declared effective as soon as practicable.
• If the registration statement is not filed within 90 days of the closing date, Exicure will be required to make pro rata payments to SangSang as liquidated damages, equal to 0.5% of the investment amount per 30-day period, subject to certain caps.
• The sale of these securities is being made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act, as it is a private placement to an accredited investor.

Sentiment

Score: 7

Explanation: The document indicates a positive development for Exicure as it secures funding, but there are some risks associated with the registration process. The sentiment is moderately positive.

Positives

• Exicure secures $2 million in funding through a private stock placement.
• The company has a clear plan for registering the resale of the shares, which provides liquidity for the investor.
• The agreement includes customary indemnification rights for both parties.

Negatives

• Exicure is subject to potential liquidated damages if the resale registration statement is delayed.
• The company is required to pay all reasonable fees and expenses related to the registration, excluding certain legal and advisor fees for SangSang.

Risks

• There is a risk of delay in filing the registration statement, which could trigger liquidated damages.
• The company is responsible for all costs associated with the registration process, which could impact profitability.
• The company is subject to potential liabilities related to the registration statements.

Future Outlook

The company intends to use the proceeds for general corporate purposes and business development.

Management Comments

• The Board of Directors of the Company has unanimously determined that this Agreement and the transactions contemplated hereby are advisable, fair and in the best interests of the Company and its stockholders.

Industry Context

This private placement is a common method for biotech companies to raise capital, especially when seeking to fund ongoing operations and development activities. It allows for a quicker infusion of capital compared to public offerings, but often comes with the need to register the shares for resale.

Comparison to Industry Standards

• Private placements are a standard method for biotech companies to raise capital, often used when speed and flexibility are needed.
• The terms of the agreement, including the registration rights and liquidated damages, are typical for this type of transaction.
• Comparable companies often use similar structures to secure funding from institutional investors.
• The pricing of $4.61 per share would need to be compared to the current market price of Exicure's stock to assess if it is a fair valuation.

Stakeholder Impact

• Shareholders will see a dilution of their ownership due to the issuance of new shares.
• The company will have additional capital to fund operations and development.
• SangSangIn Investment & Securities Co., Ltd. becomes a new significant shareholder.

Next Steps

• Exicure will close the transaction within ten days of the agreement date.
• The company will file a registration statement for the resale of the shares within 60 days of the closing date.
• Exicure will use the proceeds for general corporate purposes and business development.

Key Dates

Keywords

private placement, common stock, registration rights, capital raise, equity financing, securities, investment, SangSangIn Investment, Exicure